AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00853008
Drug: Cytosine Arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
Trial: NCT00853008
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
Trial: NCT00853008
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
Trial: NCT00853008
Drug: ASP
RxNorm normalized name: Asp
DrugBank: Aspartic acid (DB00128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
Trial: NCT00853008
Drug: Teniposide
RxNorm normalized name: Teniposide
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
Trial: NCT01296087
Drug: TC-6987
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC-6987 50 mg capsule given once daily on Days 1 to 28
Trial: NCT01125189
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
Trial: NCT01125189
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
Trial: NCT01125189
Drug: peg-interferon alfa-2a
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
Trial: NCT01125189
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
Trial: NCT03104140
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
Trial: NCT03104140
Drug: Thiopental
RxNorm normalized name: Thiopental
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
Trial: NCT01343043
Drug: NY-ESO-1(c259)T Cells
RxNorm normalized name: NYS
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
Trial: NCT01343043
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be used as lymphodepleting chemotherapy.
Trial: NCT03517176
Drug: CEND-1
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEND-1 will be provided as concentrate for solution to be administered via IV injection.
Trial: NCT03517176
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel will be provided as solution to be administered via IV infusion.
Trial: NCT03517176
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be provided as solution to be administered via IV infusion.
Trial: NCT03726593
Drug: Artesunate and Pyronaridine
RxNorm normalized name: artesunate and pyronaridine
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard weight based dosing
Trial: NCT01017874
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
Trial: NCT01017874
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
Trial: NCT01017874
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
Trial: NCT01017874
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
Trial: NCT03634969
Drug: BMS-986224
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03943043
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~1. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~2. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D.
Trial: NCT03726593
Drug: Atovaquone Proguanil and Artesunate Pyronaridine
RxNorm normalized name: proguanil and atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
Trial: NCT03726593
Drug: Atovaquone Proguanil and Artesunate Mefloquine
RxNorm normalized name: proguanil and atovaquone
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
Trial: NCT03380000
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
Trial: NCT03380000
Drug: Beetroot juice placebo
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Trial: NCT00924729
Drug: Moxifloxacin 0.5% ophthalmic solution
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer moxifloxacin study drug prior to cataract surgery.
Trial: NCT00924729
Drug: Besifloxacin 0.6% ophthalmic suspension
DrugBank: Besifloxacin (DB06771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer besifloxacin study drug prior to cataract surgery.
Trial: NCT00976729
Drug: NOX-E36
RxNorm normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
Trial: NCT00976729
Drug: NOX-E36
RxNorm normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single SC doses, at safe and tolerable dose level
Trial: NCT00455936
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gefitinib 250mg tablet/ QD daily until Progression
Trial: NCT00246064
Drug: infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01620450
Drug: biphasic human insulin 30
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
Trial: NCT00527969
Drug: HT1001 extract of Panax quinquefolius L
RxNorm normalized name: Panax quinquefolius whole extract
DrugBank: Panax quinquefolius whole (DB14296)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899182
Drug: Nitrous Oxide NO
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
Trial: NCT03904251
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT03904251
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02569801
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
Trial: NCT02569801
Drug: GDC-0810
RxNorm normalized name: GDC-0810
DrugBank: GDC-0810 (DB12253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
Trial: NCT00428246
Drug: paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mcg or 2 mcg for 4 weeks.
Trial: NCT00452296
Drug: tight insulin treatment in patients hospitalized with COPD exacerbation
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with basal plus bolus insulin
Trial: NCT00762255
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Trial: NCT00762255
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Trial: NCT03890289
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
Trial: NCT00762255
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Trial: NCT00606112
Drug: Trodusquemine (MSI-1436)
RxNorm normalized name: morphine sulfate Oral Solution [MSIR]
DrugBank: Trodusquemine (DB06333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
Trial: NCT03995485
Drug: KW-136 capsule
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-136 60 mg was provided in a single capsule of 60 mg.
Trial: NCT03995485
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir was provided in a single tablet of 400 mg.
Trial: NCT03890289
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
Trial: NCT04269369
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature.
Trial: NCT00916669
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
Trial: NCT00916669
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
Trial: NCT00916669
Drug: enoxaparin sodium
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
Trial: NCT04477707
Drug: Finerenone (BAY94-8862)
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
Trial: NCT02271334
Drug: A006 DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose 110 mcg, 1 inhalation
Trial: NCT02271334
Drug: A006 DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose 220 mcg, 1 inhalation
Trial: NCT00766012
Drug: AZD2066
RxNorm normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
Trial: NCT00299325
Drug: Rimonabant
RxNorm normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT00253435
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y.
Trial: NCT00253435
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR \>= 100 ml/min/1.72 m\^2, a dose of 300 mg/m\^2/day (10 mg/kg/day if child is \< 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m\^2, the etoposide will be administered at a dose of 160 mg/m\^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of \< 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
Trial: NCT00253435
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients in either the normal GFR strata (\>=100 ml/min/1.73 m\^2), or reduced GFR strata (60-99 ml/min/1.73m\^2), melphalan shall be administered at a dose of 60 mg/m\^2/day (2 mg/kg/day if child is \< 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration \< 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m\^2.
Trial: NCT01946620
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03779230
Drug: L19TNF
RxNorm normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
Trial: NCT05468294
Drug: Nivolumab, fixed dose
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
Trial: NCT00917748
Drug: DOCETAXEL(XRP6976) + MODAFINIL
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
Trial: NCT00917748
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
Trial: NCT00917748
Drug: Placebo of Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
Trial: NCT02179892
Drug: Bupivacaine Extended-Release Liposome Injection (Exparel)
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 266mg/30mL of Exparel will be injected via unilateral TAP block
Trial: NCT02179892
Drug: Bupivacaine and Dexamethasone Injection
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
Trial: NCT03489668
Drug: MetFORMIN 500 Mg Oral Tablet
RxNorm normalized name: metFORMIN 500 mg oral tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin administration 1500mg per day
Trial: NCT01915602
Drug: Refametinib (BAY86-9766)
RxNorm normalized name: Refametinib
DrugBank: Refametinib (DB06309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
Trial: NCT01915602
Drug: Sorafenib (BAY43-9006)
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
Trial: NCT00014430
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
Trial: NCT00305019
Drug: clevudine
RxNorm normalized name: clevudine
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04468568
Drug: Atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
Trial: NCT04468568
Drug: Terbutaline
RxNorm normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
Trial: NCT03332355
Drug: PAC-1 Compound
RxNorm normalized name: PAC-1
DrugBank: PAC-1 (DB13048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
Trial: NCT03193684
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subjects will receive daily dose of 25mg of empagliflozin for 3 months
Trial: NCT03193684
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo